Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
Belite Bio (NASDAQ:BLTE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $185.00 price target on the stock.
Belite Bio On A Tear As It Approaches Key Regulatory Submissions [Seeking Alpha]
Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
Belite Bio (NASDAQ:BLTE) is now covered by analysts at Bank of America Corporation. They set a "buy" rating and a $195.00 price target on the stock.